Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area S Wesley et al, MEDRXIV, September 29, 2020

Hot Topics of the Day|PHGKB

 Coronavirus

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
S Wesley et al, MEDRXIV, September 29, 2020

Preliminary analysis of scRNA sequencing of children's lung tissues excludes the expression of SARS-CoV-2 entry related genes as the key reason for the milder syndromes of COVID-19 in children
Y Tao et al, MEDRXIV, September 29, 2020

Functional immunoparalysis characterized by elevated Interleukin-10 and Interleukin-10-to-Lymphocyte Count Ratio is associated with severe disease and poor outcomes in coronavirus disease 2019 (COVID-19)
BM Henry et al, MEDRXIV, September 29, 2020

Coding Complete Genome Sequences of Twenty-three SARS-CoV-2 Strains Isolated in the Philippines
JS Velasco et al, MEDRXIV, September 29, 2020

DeepCOVID: An Operational Deep Learning-driven Framework for Explainable Real-time COVID-19 Forecasting
A Rodriguez et al, MEDRXIV, September 29, 2020

Artificial intelligence to predict the risk of mortality from COVID-19: Insights from a Canadian Application
B Snider et al, MEDRXIV, September 30, 2020

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov Denis Y et al. Lancet (London, England) 2020 09 (10255) 887-897

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-µg dose induced higher binding- and neutralizing-antibody titers than the 25-µg dose, which supports the use of the 100-µg dose in a phase 3 vaccine trial.

Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.
Mina Michael J et al. The New England journal of medicine 2020 Sep

It’s time to change how we think about the sensitivity of testing for Covid-19. The Food and Drug Administration (FDA) and the scientific community are currently almost exclusively focused on test sensitivity. Critically, this measure neglects the context of how the test is being used. Yet when it comes to broad screening, context is fundamental.